This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
What's in Store for Medpace Holdings (MEDP) in Q3 Earnings?
by Zacks Equity Research
Medpace Holdings' (MEDP) revenue growth in Q3 to be driven by strength in oncology, cardiometabolic, antiviral and anti-infectious diseases solutions.
Will Global Industrial Unit Boost Ecolab's (ECL) Q3 Earnings?
by Zacks Equity Research
Solid performance in the Global Industrial segment to drive Ecolab's (ECL) Q3 results.
Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus
by Sweta Jaiswal
Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.
Why Is Luminex (LMNX) Up 15% Since Last Earnings Report?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ITGR or LMNX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. LMNX: Which Stock Is the Better Value Option?
Luminex (LMNX) Misses on Earnings in Q2, Margins Contract
by Zacks Equity Research
Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.
Luminex (LMNX) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Luminex (LMNX) delivered earnings and revenue surprises of -21.05% and -0.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Earnings on Aug 6: CAH, HSIC & More
by Zacks Equity Research
The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.
Luminex (LMNX) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
Luminex (LMNX) shares rose nearly 6% in the last trading session, amid huge volumes.
Luminex (LMNX) Beats Q1 Estimates on ARIES Platform Strength
by Zacks Equity Research
Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q1; a solid guidance encourages.